Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?
about
Non-Covalent Derivatives: Cocrystals and EutecticsAcemetacin cocrystal structures by powder X-ray diffraction.Co-crystals: a novel approach to modify physicochemical properties of active pharmaceutical ingredients.Ethenzamide-gentisic acid-acetic acid (2/1/1).3-(2,4,6-Trimethyl-benzo-yl)-2-naphthoic acid.Crystal engineering of coordination polymers using 4,4'-bipyridine as a bond between transition metal atoms.Crystal engineering rescues a solution organic synthesis in a cocrystallization that confirms the configuration of a molecular ladder.Combinatorial crystal synthesis: structural landscape of phloroglucinol:1,2-bis(4-pyridyl)ethylene and phloroglucinol:phenazine.A 2:1 co-crystal of p-nitro-benzoic acid and N,N'-bis-(pyridin-3-ylmeth-yl)ethanedi-amide: crystal structure and Hirshfeld surface analysis.Cocrystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5Influence of Coformer Stoichiometric Ratio on Pharmaceutical Cocrystal Dissolution: Three Cocrystals of Carbamazepine/4-Aminobenzoic Acid.Benefits of cocrystallisation in pharmaceutical materials science: an update.New opportunities in crystal engineering--the role of atomic force microscopy in studies of molecular crystals.Cocrystallization for successful drug delivery.The A to Z of pharmaceutical cocrystals: a decade of fast-moving new science and patents.Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics.Micro-/nanostructured multicomponent molecular materials: design, assembly, and functionality.New forms of old drugs: improving without changing.Facts and fictions about polymorphism.Pharmaceutical cocrystals: along the path to improved medicines.Molecular-Level Understanding of Structural Changes of Organic Crystals Induced by Macroscopic Mechanical Stimulation.Four- and five-component molecular solids: crystal engineering strategies based on structural inequivalence.Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1.Pharmaceutical cocrystals: walking the talk.Porous Organic Molecular Frameworks with Extrinsic Porosity: A Platform for Carbon Storage and Separation.Design of co-crystals/salts of some Nitrogenous bases and some derivatives of thiophene carboxylic acids through a combination of hydrogen and halogen bonds.2-Amino-anilinium 2-carb-oxy-acetate.Improving lithium therapeutics by crystal engineering of novel ionic cocrystals.Thermal properties of molecular crystals through dispersion-corrected quasi-harmonic ab initio calculations: the case of urea.Crystal structure and hydrogen-bonding patterns in 5-fluoro-cytosinium picrate.Control of Assembly of Dihydropyridyl and Pyridyl Molecules via Directed Hydrogen BondingPropane-1,2-diaminium bis-(4-meth-oxy-benzoate).Deducing chemical structure from crystallographically determined atomic coordinates.3-Amino-pyridin-1-ium 3-carb-oxy-benzo-ate.4-Carb-oxy-pyridin-1-ium 2,4,5-tri-carb-oxy-benzoate monohydrate.Two-dimensional crystal engineering using halogen and hydrogen bonds: towards structural landscapes.Towards exhaustive and automated high-throughput screening for crystalline polymorphs.Identification of a new co-crystal of salicylic acid and benzamide of pharmaceutical relevance.A new structure of a serotonin salt: comparison and conformational analysis of all known serotonin complexes.Polymorphs, hydrates and solvates of a co-crystal of caffeine with anthranilic acid.
P2860
Q26796674-54D7DA74-DF72-467F-BCB6-91479624B9B8Q33630701-AF37528A-DB04-4445-9403-30F61FCAA287Q33834542-ACEDA467-2A82-4D43-A0B9-F17CED0B34E7Q34301770-9683801E-321C-48C7-94B6-668A16B58CE0Q34435800-8FCED37F-EE6A-40F7-B1E0-867938F9E4B6Q34572819-EF80651D-AA28-4000-A61B-1CCE71897C40Q35091038-49E51A76-198F-4ABA-8997-ECC3F34A8CF7Q35303149-B0715E69-7DF1-4270-9DB3-1CA590E805FBQ36440472-3CA23F2A-48F9-4677-8A8F-317F0EFD3C12Q37013110-1D191266-0423-4FDD-A386-E0AD499588F4Q37155004-BB0C9A72-6ED8-4CF8-A54D-7310BFDAA534Q37805586-C5AEEF5F-155B-422D-9E6E-A75CFAAEDA54Q38028473-0619C470-B68E-4C57-9EDA-84260E5DC5B4Q38068972-356647E0-D5FD-4287-9859-C0AF52C9AAB1Q38162929-F94E4579-F822-4CC6-82E2-421B29662AE0Q38236638-B336C2A7-29B7-419D-956B-BE09C1487D92Q38339833-5074BEEC-767B-4152-A09F-C0C154E86A5CQ38342804-5262002A-6F37-4EA8-907B-920C13F8B34EQ38591930-ECAF3D6F-C911-47EE-B3B2-BA19B8948807Q38632654-E2177737-4572-4B00-AF36-45108979EA12Q38691243-C5D831B5-13F5-4719-8FD0-5F5C735EB5AEQ38728095-F5A51178-C884-4344-B568-9EA39B9DE58CQ38787624-15CA3E2C-95F9-4893-A828-A97C98FF8CE2Q38856202-79404440-FAF5-4D05-A23D-705C982BC46BQ38895163-8B13BF86-E854-4A22-AB12-47D1BD21F456Q38912338-55682443-7C3A-45D8-8D9C-FF2E13A45433Q39010328-3A95F19D-3FC2-4F51-A270-48AB576C8BC3Q39066912-9402ECBE-4FB7-4A49-AC5C-76417EC5CB6DQ40209734-62882D69-7E4D-4025-84A1-BF9002B7FB4FQ41864040-3931F978-A41F-4616-AE76-6F74B373428AQ41906571-E060B193-BCD7-4836-BFA7-9C639A4A2096Q42119772-61CCB211-3020-445A-B334-A6EDE622B172Q42147157-2E949F40-B934-4D28-B450-8C2493F8B4E7Q42148307-E6290444-C407-414B-B6A1-2AEACC74C1EFQ42236303-282AD7C8-7FC3-4215-B08E-E9F67699E8C9Q42274130-D7E6A13F-1C1D-4A39-A852-36E7E532643AQ42970508-C852941C-35A9-4CA5-A799-EB52E1203C23Q43206052-79455680-E227-4460-9A33-0B45B60E7A69Q43449535-5FEE7893-A0D6-421A-9D11-1EA7C7F1D00EQ44983103-E8F85EA4-CDDA-4FFB-8A73-A3753534B1A2
P2860
Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Crystal engineering of the com ...... ew path to improved medicines?
@en
Crystal engineering of the com ...... ew path to improved medicines?
@nl
type
label
Crystal engineering of the com ...... ew path to improved medicines?
@en
Crystal engineering of the com ...... ew path to improved medicines?
@nl
prefLabel
Crystal engineering of the com ...... ew path to improved medicines?
@en
Crystal engineering of the com ...... ew path to improved medicines?
@nl
P356
P1476
Crystal engineering of the com ...... ew path to improved medicines?
@en
P2093
Orn Almarsson
P304
P356
10.1039/B402150A
P407
P577
2004-08-05T00:00:00Z